- Caregivers of people with advanced cancer often find that psychedelic-assisted therapy can strengthen their relationships and provide a sense of hope during difficult times.
- The well-being of a patient and their caregiver are deeply connected, meaning that supporting the caregiver is just as important as supporting the patient.
- While some family members initially feel hesitant about using LSD, many eventually see the value in how it helps address existential distress and improves communication.
Summary of It’s all about the relationship: The caregiver experience of supporting a person with advanced cancer going through an LSD microdosing trial
Introduction
Advanced cancer impacts more than just the person receiving the diagnosis; it profoundly affects the informal caregivers who provide emotional, practical, and decision-making support. These family members and friends often carry a heavy burden, yet their perspectives are frequently overlooked in medical research. This oversight is particularly significant in the field of psychedelic-assisted care, where the stigma surrounding substances like LSD can cause hesitation or concern within a patient’s family.
Researchers wanted to understand the hopes, beliefs, and experiences of caregivers supporting patients in a randomized feasibility trial. This specific trial combined LSD microdoses or a placebo with meaning-centered psychotherapy (MCP), an approach designed to help people find purpose during end-of-life care. By looking at the caregiver’s side of this relationship, the researchers aimed to explore how the psychedelic component and the psychotherapy influenced both the patient’s well-being and the strength of their bond with their loved one.
Methods
This qualitative research was conducted as part of the larger Psychedelic-Assisted Meaning-Centred Psychotherapy (PAM) feasibility trial. In that trial, patients with advanced cancer received weekly MCP for seven weeks and were randomly assigned to receive either 13 microdoses of LSD or 13 placebo doses. The trial was double-blinded, meaning that neither the patients, their caregivers, the researchers, nor the therapists knew which treatment the patient was receiving.
The sample included caregivers linked to 15 unique cancer patients, mostly consisting of spouses or long-term partners. Participants were interviewed twice: once at the start of the patient’s treatment and again about one month after the treatment concluded. These semi-structured interviews allowed for deep discussion regarding the caregiver’s perceptions. The data were analyzed using reflexive thematic analysis to identify the core experiences shared by those supporting the patients.
Results
The caregivers involved in the study ranged in age from their mid-30s to their mid-80s, with most being female and of NZ European descent. The analysis revealed several key themes regarding how they experienced the journey of supporting a loved one through the trial.
The oppression of the illness
Caregivers described the overwhelming weight of advanced cancer, noting the shock of diagnosis and the constant demands of medical treatments. They spoke about the disruption to family routines, financial pressures, and the deep psychological burden of facing an uncertain future. A central finding was that the well-being of the patient and the caregiver were closely intertwined, with the struggles of one person directly impacting the other.
Supporting the trial experience
Many caregivers felt supportive of the trial, hoping it would help their loved one find meaning or feel useful. However, some initially felt hesitant because LSD is often perceived as a powerful or stigmatized drug. Despite these concerns, some participants viewed the trial as a meaningful way to contribute to scientific progress and help future patients.
Making the most of now, ideally
The experience of advanced cancer often prompted a shift in perspective, where caregivers began to prioritize the quality of the present moment. They focused on engaging in enjoyable shared activities, avoiding unnecessary conflict, and making sure the time remaining was used as meaningfully as possible. The trial was sometimes viewed as a tool to help facilitate this focused way of living.
Hope is an antidote to desperation
Hope served as a vital tool for caregivers to manage fear and despair. This hope was often tied to the patient’s improved well-being and the possibility of stronger relationships. For some, even a small sense of hope acted as a buffer against the overwhelming uncertainty of the illness.
The primacy of relationships
The illness and the trial itself seemed to sharpen the importance of close connections. Caregivers reported more honest communication and a greater appreciation for their relationship with the patient. They noted that the experience encouraged them to respond more constructively to one another and to value mutual support more deeply.
Discussion
Researchers interpret these findings as evidence that caregiver and patient well-being are bidirectionally linked. Because caregiving in the context of advanced cancer is so pervasive, the trial made it clear that what affects the patient almost inevitably affects the person supporting them. This highlights the need to view cancer care through a “dyadic” lens, looking at the patient and their support system as a single unit.
The results align with previous research suggesting that the emotional and practical strain of cancer is immense for informal caregivers. Furthermore, the hesitation some caregivers felt regarding LSD mirrors earlier findings that stigma can impact participation in psychedelic research. Conversely, the positive shifts in meaning-making and communication described in this study are consistent with the known benefits of meaning-centered psychotherapy and open end-of-life communication.
Several limitations must be considered. Because this was a feasibility study, it was not designed to provide statistical proof of change. Additionally, because the study remained double-blinded, it was impossible to compare whether caregivers of those receiving LSD had different experiences than those whose loved ones received a placebo. The qualitative nature of the work means these findings describe experiences rather than proving that the LSD or the therapy caused specific outcomes.
Conclusion
The patient-caregiver relationship is a vital component of advanced cancer care, and interventions are likely to be more effective when they include both members of the dyad. The combination of meaning-centered psychotherapy and LSD microdosing appeared to help address existential distress and encouraged more open conversations about death and difficult topics. While more research is needed to confirm these effects, the results suggest a promising path forward.
Future clinical trials should prioritize including caregivers to capture a more complete picture of the cancer experience. Holistic palliative care should aim to support the entire family, incorporating approaches that foster hope, support, and stronger relationships. By focusing on the caregiver, healthcare providers can better support the patients who rely on them. See also our coverage of LSD microdosing in major depressive disorder, and our explainers on medical applications. Read the full paper summary on Blossom.
